Tag: Sensipar

The U.S. Food and Drug Administration (FDA) first approved generic versions of cinacalcet on March 8, 2018. This milestone introduced competition for the brand-name drug Sensipar, which had sales of $1.72 billion in 2017. The question of *when did cinacalcet go generic?* is pivotal for understanding patient access and cost.

In 2004, cinacalcet was approved by the FDA as the first agent in its class, definitively answering the question, 'What category is cinacalcet?' and ushering in a new treatment option for hyperparathyroidism. This medication is classified as a calcimimetic agent and is used to manage specific conditions involving overactive parathyroid glands.

Between 25% and 66% of patients taking cinacalcet report significant gastrointestinal side effects, such as nausea and vomiting, leading many to seek alternative treatments. Deciding what can be used instead of cinacalcet is a complex process that depends on the specific type of hyperparathyroidism, patient tolerance, and other co-existing medical conditions.

For many patients with chronic conditions such as secondary hyperparathyroidism or certain forms of parathyroid cancer, cinacalcet therapy is a long-term or even lifelong commitment. The precise length of time for how long can you take cinacalcet for is highly dependent on the underlying condition, the patient's individual response to treatment, and consistent medical supervision.

Cinacalcet is a prescription-only medication, approved by the FDA for treating serious conditions related to parathyroid hormone imbalances. This strict classification is why you cannot **buy cinacalcet over the counter**, as its use requires careful medical oversight to manage efficacy and potential side effects.

Cinacalcet (brand name Sensipar) is a calcimimetic agent that works by increasing the sensitivity of the calcium-sensing receptors on the parathyroid glands to extracellular calcium. It is an important medication for controlling high parathyroid hormone (PTH) levels, and the generic version offers a potentially more affordable option for many patients.

A 2024 meta-analysis revealed that the global prevalence of secondary hyperparathyroidism (SHPT) due to chronic kidney disease (CKD) is approximately 49.5% [1.7.1, 1.7.2]. A key medication to manage this is cinacalcet, but what's another name for cinacalcet? The most common brand name is Sensipar [1.2.1].

A study published in the *New England Journal of Medicine* showed cinacalcet treatment significantly reduced serum phosphorus levels in dialysis patients with secondary hyperparathyroidism. However, the answer to **does cinacalcet affect phosphorus** isn't a simple yes or no; its impact depends on the patient's specific condition and overall mineral regulation.

Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), with a global prevalence estimated at 49.5%. To manage this and related conditions, a key question for patients and providers is, **what is Cinacalcet?** It's a vital medication for controlling hormone levels.

According to a 2013 meta-analysis, Cinacalcet significantly reduces the need for parathyroidectomy in patients with chronic kidney disease on dialysis. A calcimimetic drug, Cinacalcet tablets are primarily used to manage specific conditions involving overactive parathyroid glands and high calcium levels in the blood. This medication works by increasing the sensitivity of the body's calcium-sensing receptors, which in turn lowers parathyroid hormone (PTH) and calcium levels.